Common Stock, Shares, Issued of Spyre Therapeutics, Inc. from 31 Dec 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Summary
Spyre Therapeutics, Inc. quarterly Common Stock, Shares, Issued in shares history and change rate from 31 Dec 2015 to 30 Sep 2025.
  • Spyre Therapeutics, Inc. Common Stock, Shares, Issued for the quarter ending 30 Sep 2025 was 60,471,793, a 18% increase year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares, Issued, Quarterly (shares)
Common Stock, Shares, Issued, YoY Quarterly Change (%)

Spyre Therapeutics, Inc. Quarterly Common Stock, Shares, Issued (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 60,471,793 +9,076,185 +18% 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 60,372,927 +9,589,543 +19% 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 60,275,561 +23,645,881 +65% 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 60,257,023 +24,199,914 +67% 31 Dec 2024 10-Q 04 Nov 2025 2025 Q3
Q3 2024 51,395,608 +47,346,921 +1169% 30 Sep 2024 10-Q/A 18 Nov 2024 2024 Q3
Q2 2024 50,783,384 -30,218,292 -37% 30 Jun 2024 10-Q/A 18 Nov 2024 2024 Q2
Q1 2024 36,629,680 -28,765,479 -44% 31 Mar 2024 10-Q/A 18 Nov 2024 2024 Q1
Q4 2023 36,057,109 +33,443,095 +1279% 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 4,048,687 -57,462,391 -93% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 81,001,676 +19,829,166 +32% 30 Jun 2023 10-Q 11 Aug 2023 2023 Q2
Q1 2023 65,395,159 +15,975,286 +32% 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 2,614,014 -46,741,116 -95% 31 Dec 2022 10-K/A 18 Nov 2024 2023 FY
Q3 2022 61,511,078 +12,204,971 +25% 30 Sep 2022 10-Q 03 Nov 2022 2022 Q3
Q2 2022 61,172,510 +12,146,554 +25% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 49,419,873 +399,972 +0.82% 31 Mar 2022 10-Q 05 May 2022 2022 Q1
Q4 2021 49,355,130 +1,396,044 +2.9% 31 Dec 2021 10-K 02 Mar 2023 2022 FY
Q3 2021 49,306,107 +4,614,077 +10% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 49,025,956 +4,426,109 +9.9% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 49,019,901 +19,872,440 +68% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 47,959,086 +18,874,649 +65% 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q3 2020 44,692,030 +15,768,789 +55% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 44,599,847 +15,751,544 +55% 30 Jun 2020 10-Q 10 Aug 2020 2020 Q2
Q1 2020 29,147,461 +310,109 +1.1% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 29,084,437 +4,944,340 +20% 31 Dec 2019 10-K 18 Mar 2021 2020 FY
Q3 2019 28,923,241 +6,825,023 +31% 30 Sep 2019 10-Q 06 Nov 2019 2019 Q3
Q2 2019 28,848,303 +6,940,111 +32% 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 28,837,352 +12,027,683 +72% 31 Mar 2019 10-Q 07 May 2019 2019 Q1
Q4 2018 24,140,097 +7,469,909 +45% 31 Dec 2018 10-K 24 Feb 2020 2019 FY
Q3 2018 22,098,218 +5,625,387 +34% 30 Sep 2018 10-Q 08 Nov 2018 2018 Q3
Q2 2018 21,908,192 +5,455,932 +33% 30 Jun 2018 10-Q 09 Aug 2018 2018 Q2
Q1 2018 16,809,669 +3,357,409 +25% 31 Mar 2018 10-Q 08 May 2018 2018 Q1
Q4 2017 16,670,188 +3,239,355 +24% 31 Dec 2017 10-K 07 Mar 2019 2018 FY
Q3 2017 16,472,831 +3,041,998 +23% 30 Sep 2017 10-Q 07 Nov 2017 2017 Q3
Q2 2017 16,452,260 +3,040,488 +23% 30 Jun 2017 10-Q 09 Aug 2017 2017 Q2
Q1 2017 13,452,260 +12,694,924 +1676% 31 Mar 2017 10-Q 09 May 2017 2017 Q1
Q4 2016 13,430,833 +12,673,497 +1673% 31 Dec 2016 10-K 13 Mar 2018 2017 FY
Q3 2016 13,430,833 30 Sep 2016 10-Q 09 Nov 2016 2016 Q3
Q2 2016 13,411,772 30 Jun 2016 10-Q 09 Aug 2016 2016 Q2
Q1 2016 757,336 31 Mar 2016 10-Q 19 May 2016 2016 Q1
Q4 2015 757,336 31 Dec 2015 10-K 23 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.